These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34963881)

  • 1. A potential hypothesis for 2019-nCoV infection therapy through delivery of recombinant ACE2 by red blood cell-hitchhiking.
    Aghili ZS; Mirzaei SA; Banitalebi-Dehkordi M
    J Biol Res (Thessalon); 2020 Dec; 27():17. PubMed ID: 34963881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells.
    Anselmo AC; Gupta V; Zern BJ; Pan D; Zakrewsky M; Muzykantov V; Mitragotri S
    ACS Nano; 2013 Dec; 7(12):11129-37. PubMed ID: 24182189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.
    Zhuang MW; Cheng Y; Zhang J; Jiang XM; Wang L; Deng J; Wang PH
    J Med Virol; 2020 Nov; 92(11):2693-2701. PubMed ID: 32497323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE2 and COVID-19 and the resulting ARDS.
    Zhang X; Li S; Niu S
    Postgrad Med J; 2020 Jul; 96(1137):403-407. PubMed ID: 32522846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
    van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
    Elife; 2020 Apr; 9():. PubMed ID: 32338605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.
    Kruse RL
    F1000Res; 2020; 9():72. PubMed ID: 32117569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.
    Veeramachaneni GK; Thunuguntla VBSC; Bobbillapati J; Bondili JS
    J Biomol Struct Dyn; 2021 Jul; 39(11):4015-4025. PubMed ID: 32448098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in research on ACE2 as a receptor for 2019-nCoV.
    Wu J; Deng W; Li S; Yang X
    Cell Mol Life Sci; 2021 Jan; 78(2):531-544. PubMed ID: 32780149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2.
    Hu S; Wang J; Zhang Y; Bai H; Wang C; Wang N; He L
    J Med Virol; 2021 May; 93(5):3143-3151. PubMed ID: 33580518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods.
    Marofi F; Azizi R; Motavalli R; Vahedi G; Nasimi M; Yousefi M; Motavalli Y; Tahmasebi S; Gharibi T; Mohammed RN; Etemadi J; Khiavi FM
    Anticancer Agents Med Chem; 2021 Oct; 21(16):2142-2162. PubMed ID: 33563186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Red blood cell-hitchhiking mediated pulmonary delivery of ivermectin: Effects of nanoparticle properties.
    Zheng J; Lu C; Ding Y; Zhang J; Tan F; Liu J; Yang G; Wang Y; Li Z; Yang M; Yang Y; Gong W; Gao C
    Int J Pharm; 2022 May; 619():121719. PubMed ID: 35390488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lessons from SARS: a new potential therapy for acute respiratory distress syndrome (ARDS) with angiotensin converting enzyme 2 (ACE2)].
    Imai Y; Kuba K; Penninger JM
    Masui; 2008 Mar; 57(3):302-10. PubMed ID: 18340998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting shape, cellular-hitchhiking and antibodies to target nanoparticles to lung endothelium: Synergy between physical, chemical and biological approaches.
    Anselmo AC; Kumar S; Gupta V; Pearce AM; Ragusa A; Muzykantov V; Mitragotri S
    Biomaterials; 2015 Nov; 68():1-8. PubMed ID: 26241497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Sequence Hot-spots for Binding of nCOV-2019 to ACE2 as Evaluated by Molecular Simulations.
    Ghorbani M; Brooks BR; Klauda JB
    bioRxiv; 2020 Jun; ():. PubMed ID: 32637962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding affinity improvement analysis of multiple-mutant Omicron on 2019-nCov to human ACE2 by in silico predictions.
    Li B; Guo J; Hu W; Chen Y
    J Mol Model; 2023 Apr; 29(5):155. PubMed ID: 37093365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection.
    Zou X; Chen K; Zou J; Han P; Hao J; Han Z
    Front Med; 2020 Apr; 14(2):185-192. PubMed ID: 32170560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme 2 protects from severe acute lung failure.
    Imai Y; Kuba K; Rao S; Huan Y; Guo F; Guan B; Yang P; Sarao R; Wada T; Leong-Poi H; Crackower MA; Fukamizu A; Hui CC; Hein L; Uhlig S; Slutsky AS; Jiang C; Penninger JM
    Nature; 2005 Jul; 436(7047):112-6. PubMed ID: 16001071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral drugs suppress infection of 2019-nCoV spike pseudotyped virus by interacting with ACE2 protein.
    Wang J; Zhang Y; Hu S; Bai H; Xue Z; Liu Y; Ma W
    J Biochem Mol Toxicol; 2022 Feb; 36(2):e22948. PubMed ID: 34755435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE2 as a Potential Target for Management of Novel Coronavirus (nCoV- 2019).
    Foroozanfar E; Forouzanfar M; Farkhondeh T; Samarghandian S; Forouzanfar F
    Curr Drug Discov Technol; 2021; 18(6):e130921189567. PubMed ID: 33371835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.